血球脂可预测2型糖尿病患者晚期肝纤维化发展
Sarah Béland-Bonenfant1, Damien Denimal2, Jean-Paul Pais-de-Barros3
1Department of Endocrinology, Diabetology, and Nutrition, INSERM, CTM UMR 1231, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France.
Diabetes, obesity & metabolism
|September 24, 2025
概括
两个等离子体脂,d18:1/18:0米林和d18:0/20:0二胺,预测2型糖尿病患者的晚期肝纤维化 (AF). 这些生物标志物可以识别高风险的个体对不良结果.
科学领域:
- 生物化学 生物化学
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
背景情况:
- 患有2型糖尿病 (T2D) 的患者面临患有代谢功能障碍相关脂肪性肝病 (MASLD) 的风险增加.
- 在MASLD中,进展到晚期肝纤维化 (AF) 与健康状况不佳有关.
- 脂质在MASLD和AF的发展和进展中起着至关重要的作用.
研究的目的:
- 确定特定的脂质体生物标志物,用于预测T2D患者的AF发展.
- 在T2D队列中研究血脂类物种对AF的预测能力.
主要方法:
- 一组67名T2D患者被跟踪平均10.2年.
- 测量了148种脂类 (脂,脂,自由脂肪酸) 的基线血度.
- 使用肝硬度测量 (≥8.0 kPa) 和肝硬化的超声波标志来评估晚期肝纤维化 (AF).
主要成果:
- 在随访期间,20.9%的患者出现了晚期肝纤维化 (AF).
- 原始血水平d18:1/18:0斯芬戈米林和d18:0/20:0二胺是AF的显著预测因素.
- 机器学习确定了这两种脂蛋白是AF最强大的独立预测因素.
结论:
- 血脊脂水平d18:1/18:0脊髓和d18:0/20:0二胺是T2D患者AF的独立预测剂.
- 这些生物标志物可以帮助识别患有肝脏和肝外并发症高风险的T2D患者.
- 这些发现可能有助于制定针对T2D相关肝病的向治疗策略.
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
565
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
565
Blood Studies for Cardiovascular System III: Serum Lipid Profile
557
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
557
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
215
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
215


